XBP1 and cancer: Strikingly, STF-080310, a novel IRE1α/XBP1 inhibitor, can sensitize resistant MCF7 cancer cells to tamoxifen through specifically disrupting the splicing of XBP1 and reducing the expression level of XBP1s (Papandreou et al., 2011; Ming et al., 2015).